References
- Atkinson JB, Connor DH, Robinowitz M, et al. Cardiac fungal infections: review of autopsy findings in 60 patients. Hum Pathol 1984; 15: 935–42.
- Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–803.
- Williams AH. Aspergillus myocarditis. Am J Clin Pathol 1974; 61: 247–56.
- Rüchel R, Schaffrinski M. Versatile fluorescent staining of fungi in clinical specimens by using the optical brightener Blankophor. J Clin Microbiol 1999; 37: 2694–6.
- Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696–709.
- Lin SJ, Schranz J, Teutsch M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–66.
- Rankin NE. Disseminated aspergillosis and moniliasis associated with agranulocytosis and antibiotic therapy. Br Med J 1953; 183: 918–9.
- Schwartz DA. Aspergillus pancarditis following bone marrow transplantation for chronic myelogenous leukemia. Chest 1989; 95: 1338–9.
- Young RC, Bennett JE, Vogel CL, et al. Aspergillosis: the spectrum of disease in 98 patients. Medicine (Baltimore) 1970; 49: 147–73.
- Boon AP, O’Brien D, Adams DH. 10 year review of invasive aspergillosis detected at necropsy. J Clin Pathol 1991; 44: 452–4.
- Rogers JG, Windle JR, McManus BM, et al. Aspergillus myocarditis presenting as myocardial infarction with complete heart block. Am Heart J 1990; 120: 430–2.
- Rouby Y, Combourieu E, Perrier-Gros-Claude JD, et al. A case of Aspergillus myocarditis associated with septic shock. J Infect 1998; 37: 295–7.
- Bennett JE. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone, 1995: 2306–11.
- Wiest PM, Flanigan T, Salata RA, et al. Serious infectious complications of corticosteroid therapy for COPD. Chest 1989; 95: 1180–4.
- De Meo AN, Anderson BR. Defective chemotaxis associated with a serum inhibitor in cirrhotic patients. N Engl J Med 1972; 286: 735–9.
- Jenssen HE, Salonen J, Ekfors TO. The use of immunohisto-chemistry to improve sensitivity and specificity in the diagnosis of systemic mycoses in patients with haematological malignancies. J Pathol 1997; 181: 100–5.
- Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343: 1388–98.
- Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–15.
- Connors AF Jr, Dawson NV, Thomas C, et al. Outcome following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996; 154: 959–67.
- Albert RK, Martin TR, Lewis SW. Controlled trial of methyl-prednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92: 753–8.
- Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407–12.
- Bullard MJ, Liaw S, Tsai Y, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med 1996; 14: 139–43.
- Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941–7.
- Davies L, Angus RM, Calverley PMA. Oral corticosteroid in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456–60.
- McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD: a critical review. Chest 1997; 111: 732–43.
- Celli B. Standards for the optimal management of COPD. Chest 1998; 113: 283S–7S.